Effect of metabolic traits on the risk of cirrhosis and hepatocellular cancer in nonalcoholic fatty liver disease

Cited by (320)

Items 101–200 of 320

1. Integrating Artificial Intelligence in the Diagnosis and Management of Metabolic Syndrome: A Comprehensive Review
   Jingjing Liu, Zhangdaihong Liu, Chang Liu, Hong Qiang Sun, Xiaoguang Li, Yang Yang · 2025 · Diabetes/Metabolism Research and Reviews
2. Glycemic control target for liver and cardiovascular events risk in metabolic dysfunction‐associated steatotic liver disease
   Nobuharu Tamaki, Shun‐ichi Wakabayashi, Takefumi Kimura, Yutaka Yasui, Kaoru Tsuchiya, Hiroyuki Nakanishi, Daniel Q. Huang, Takeji Umemura, Masayuki Kurosaki, Namiki Izumi · 2024 · Hepatology Research
3. NAFLD in lean individuals: not a benign disease
   Sven Francque, Vincent Wai‐Sun Wong · 2021 · Gut
4. Liver Fibrosis Marker and Postoperative Mortality in Patients Without Overt Liver Disease
   Shira Zelber‐Sagi, Vikas N. O’Reilly-Shah, Christine T. Fong, Dana Ivancovsky Wajcman, May J. Reed, Itay Bentov · 2022 · Anesthesia & Analgesia
5. Molecular Mechanisms Linking Nonalcoholic Steatohepatitis to Cancer
   Kara Wegermann, Jeongeun Hyun, Anna Mae Diehl · 2021 · Clinical Liver Disease
6. Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO)
   Associazione Italiana per lo Studio del Fegato (AISF), Società Italiana di Diabetologia (SID) and Società Italiana dell’Obesità (SIO) · 2021 · Eating and Weight Disorders - Studies on Anorexia Bulimia and Obesity
7. The Current View of Nonalcoholic Fatty Liver Disease-Related Hepatocellular Carcinoma
   Tomomi Kogiso, Katsutoshi Tokushige · 2021 · Cancers
8. Metabolic syndrome traits differentially and cumulatively influence micro‐ and macrovascular disease risk in patients with MASLD
   Alex E. Henney, David R. J. Riley, Theresa Hydes, Matthew Anson, Gema H. Ibarburu, Sizheng Steven Zhao, Daniel James Cuthbertson, Uazman Alam · 2024 · Liver International
9. Metabolic dysfunction-associated steatotic liver disease (MASLD): a systemic disease with a variable natural history and challenging management
   Luigi Elio Adinolfi, Aldo Marrone, Luca Rinaldi, Riccardo Nevola, Antonio Izzi, Ferdinando Carlo Sasso · 2025 · Exploration of Medicine
10. Metabolic-Associated Fatty Liver Disease, Hepatitis B Surface Antigen Seroclearance, and Long-Term Risk of Hepatocellular Carcinoma in Chronic Hepatitis B
    Ming‐Whei Yu, Chih‐Lin Lin, Chun‐Jen Liu, Wan‐Jung Wu, Jui‐Ting Hu, Yi‐Wen Huang · 2022 · Cancers
11. Factors That Predict the Progression of Non-alcoholic Fatty Liver Disease (NAFLD)
    Madhangi Parameswaran, Hamzah A Hasan, Jafor Sadeque, Sharan Jhaveri, Chaithanya Avanthika, Abimbola E Arisoyin, Maulik Dhanani, Swaroopa Madhuri Rath · 2021 · Cureus
12. Association between nontraditional lipid parameters and the risk of type 2 diabetes and prediabetes in patients with nonalcoholic fatty liver disease: from the national health and nutrition examination survey 2017–2020
    Jierui Liu, Qingan Fu, Ruolin Su, Rixiang Liu, Shisheng Wu, Ke Li, Jianhua Wu, Nuobei Zhang · 2024 · Frontiers in Endocrinology
13. Subclinical atherosclerosis and arterial stiffness in nonalcoholic fatty liver disease: A case-control study in Algerian population
    S. Taharboucht, Rachida Guermaz, M. Brouri, A. Chibane · 2021 · JMV-Journal de Médecine Vasculaire
14. Correlation analysis of metabolic characteristics and the risk of metabolic-associated fatty liver disease - related hepatocellular carcinoma
    Xuancheng Xie, Mengyao Zheng, Weibo Guo, Ying Zhou, Zhao Xiang, Yuting Li, Jinhui Yang · 2022 · Scientific Reports
15. Modifiable Risk Factors for Hepatocellular Carcinoma in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease: A Meta-Analysis
    Shiyu Xiao, Ya Liu, Xiliang Fu, Tong Chen, Wenhui Xie · 2024 · The American Journal of Medicine
16. Association between RC/HDL-C ratio and risk of non-alcoholic fatty liver disease in the United States
    Yanyan Xuan, Weike Hu, Yudan Wang, Jingwen Li, Lisha Yang, Songping Yu, Dongdong Zhou · 2024 · Frontiers in Medicine
17. The potential of insulin resistance indices to predict non-alcoholic fatty liver disease in patients with type 2 diabetes
    Jie Tian, Yu-tian Cao, Wenhui Zhang, Aiyao Wang, Xinyi Yang, Yinfeng Dong, Xiqiao Zhou · 2024 · BMC Endocrine Disorders
18. Obesity Management of Liver Transplant Waitlist Candidates and Recipients
    Danielle Brandman · 2020 · Clinics in Liver Disease
19. Association of metabolic traits with occurrence of nonalcoholic fatty liver disease-related hepatocellular carcinoma
    Jin Chen, Shu Song, Xiangsu Li, Dongxue Bian, Xudong Wu · 2021 · Saudi Journal of Gastroenterology
20. A Genetic and Metabolic Staging System for Predicting the Outcome of Nonalcoholic Fatty Liver Disease
    Grazia Pennisi, Rosaria Maria Pipitone, Marco Enea, Antonio De Vincentis, Salvatore L Battaglia, Vito Di Marco, Vincenzo Di Martino, Federica Spatola, Federica Tavaglione, Umberto Vespasiani Gentilucci et al. · 2022 · Hepatology Communications
21. Risk-stratified hepatocellular carcinoma surveillance in non-cirrhotic patients with MASLD
    Ke Mi, Tingdan Ye, Lin Zhu, Calvin Q. Pan · 2025 · Gastroenterology report
22. From Non-Alcoholic Fatty Liver Disease to Liver Cancer: Microbiota and Inflammation as Key Players
    Avilene Rodríguez‐Lara, Ascensión Rueda‐Robles, María José Sáez‐Lara, Julio Plaza‐Díaz, Ana I. Álvarez‐Mercado · 2023 · Pathogens
23. Alcohol and Hepatocellular Carcinoma
    Nghiem B. Ha, Francis Y. Yao · 2024 · Clinics in Liver Disease
24. Preparing for the NASH epidemic: A call to action
    Fasiha Kanwal, Jay H. Shubrook, Zobair M. Younossi, Yamini Natarajan, Elisabetta Bugianesi, Mary Eugenia Rinella, Stephen A. Harrison, Christos Socrates Mantzoros, Kim M. Pfotenhauer, Samuel Klein et al. · 2021 · Obesity
25. Liver diseases: Perspective from the Philippines
    Eric David B. Ornos, Karl Jeffrey Murillo, Janus P. Ong · 2023 · Annals of Hepatology
26. Nonalcoholic fatty liver disease-related hepatocellular carcinoma growth rates and their clinical outcomes
    Jihane N. Benhammou, Jonathan Lin, Elizabeth S. Aby, Daniela Markovic, Steven S. Raman, David Lu, Myron John Tong · 2021 · Hepatoma Research
27. An Overview of Hepatocellular Carcinoma Surveillance Focusing on Non-Cirrhotic NAFLD Patients: A Challenge for Physicians
    Annalisa Cespiati, Felice Cinque, Marica Meroni, Rosa Lombardi, Paola Dongiovanni, Anna Ludovica Fracanzani · 2023 · Biomedicines
28. MBOAT7 rs641738 (C>T) is associated with NAFLD progression in men and decreased ASCVD risk in elder Chinese population
    Xiaoyi Xu, Hangfei Xu, Xiaohui Liu, Shuang Zhang, Zhenhuan Cao, Lixia Qiu, Xiaofei Du, Yali Liu, Gang Wang, Li Zhang et al. · 2023 · Frontiers in Endocrinology
29. Clinical care guidance in patients with diabetes and metabolic dysfunction–associated steatotic liver disease: A joint consensus
    Jee‐Fu Huang, Tien‐Jyun Chang, Ming‐Lun Yeh, Feng‐Chih Shen, Chi‐Ming Tai, Jung‐Fu Chen, Yi‐Hsiang Huang, Chih‐Yao Hsu, Pin‐Nan Cheng, Ching‐Ling Lin et al. · 2024 · Hepatology Communications
30. Association between hypertension and nonalcoholic fatty liver disease: a cross-sectional and meta-analysis study
    Qingzhi Huang, Hana Yu, Xin Zhong, Ying Tian, Zhenhua Cui, Zhenyu Quan · 2022 · Journal of Human Hypertension
31. A machine learning-based classification of adult-onset diabetes identifies patients at risk of liver-related complications
    Lukas Otero Sanchez, Clara-Yongxiang Zhan, Carolina Gomes da Silveira Cauduro, Laurent Crenier, Hassane Njimi, Gaël Englebert, Antonella Putignano, Antonia Lepida, Delphine Degré, Nathalie Boon et al. · 2023 · JHEP Reports
32. Comorbid Chronic Diseases and Survival in Compensated and Decompensated Cirrhosis: A Population-Based Study
    Sumeet K. Asrani, Lauren Hall, Vikrant Reddy, Gerald Ogola, Manhal J. Izzy · 2022 · The American Journal of Gastroenterology
33. Liver Fibrosis in Non-Alcoholic Fatty Liver Disease and Progression to Hepatocellular Carcinoma in Patients with Inflammatory Bowel Disease: A Systematic Review
    Samuel J. Martínez‐Domínguez, Sandra G. García, Viviana Laredo, Carla J. Gargallo-Puyuelo, Beatriz Gallego Llera, Julia López de la Cruz, Fernando Gomollón · 2023 · Cancers
34. The emerging role of E3 ubiquitin ligases and deubiquitinases in metabolic dysfunction-associated steatotic liver disease
    Yu Long Zhang, Jiahui Yang, Jiali Min, Shan Hong Huang, Yuchen Li, Shanshan Liu · 2025 · Journal of Translational Medicine
35. Longitudinal changes in cardiometabolic risk factors are associated with changes in liver stiffness in adults with MASLD
    Matthew Dukewich, Laura A. Wilson, Jennifer L. Dodge, Liyun Yuan, Bilal Hameed, Katherine P. Yates, Rohit Seth Loomba, Brent A. Neuschwander‐Tetri, Wendy Jean Mack, Norah A. Terrault · 2026 · Journal of Hepatology
36. Nonalcoholic Fatty Liver Disease
    Terry Cheuk‐Fung Yip, Grace Lai‐Hung Wong, Vincent Wai‐Sun Wong, George Boon‐Bee Goh, Wah‐Kheong Chan · 2023 · Medical Clinics of North America
37. Hepatocellular carcinoma in nonalcoholic fatty liver disease: A growing challenge
    Â. Mattos, J. Debes, R. Dhanasekaran, J. Benhammou, M. Arrese, André Luiz V. Patrício, A. C. Zilio, Angelo A. Mattos · 2021 · World Journal of Hepatology
38. Nonalcoholic Fatty Liver Disease-Related Hepatocellular Carcinoma: The Next Threat after Viral Hepatitis
    Mohamed Salaheldin, Heba Ismail Saad Aly, Louis Ho Shing Lau, Shimaa Afify, Mohamed El‐Kassas · 2023 · Diagnostics
39. Which Comes First, Nonalcoholic Fatty Liver Disease or Arterial Hypertension?
    Julia A. Golubeva, Anna F. Sheptulina, Anastasiya Yu. Elkina, Ekaterina O. Liusina, Anton R. Kiselev, Oxana M. Drapkina · 2023 · Biomedicines
40. Diagnostics and omics technologies for the detection and prediction of metabolic dysfunction-associated steatotic liver disease-related malignancies
    Tian Lan, Frank Tacke · 2024 · Metabolism
41. Single nucleotide polymorphisms in telomere length-related genes are associated with hepatocellular carcinoma risk in the Chinese Han population
    Peng Huang, Rong Li, Lin Shen, Weizhou He, Shuo Chen, Yu Dong, Jiancang Ma, Xi Chen, Meng Michelle Xu · 2020 · Therapeutic Advances in Medical Oncology
42. Molecular Genealogy of Metabolic-associated Hepatocellular Carcinoma
    Takahiro Kodama, Tetsuo Takehara · 2024 · Seminars in Liver Disease
43. Selecting the Target Population for Screening of Hepatic Fibrosis in Primary Care Centers in Korea
    Huiyul Park, Eileen Laureal Yoon, Mimi Kim, Seon Cho, Jung Hwan Kim, Dae Won Jun, Eun‐Hee Nah · 2022 · Journal of Clinical Medicine
44. Immunotherapy for nonalcoholic fatty liver disease-related hepatocellular carcinoma: Lights and shadows
    F. Costante, Carlo Airola, F. Santopaolo, A. Gasbarrini, M. Pompili, F. Ponziani · 2022 · World Journal of Gastrointestinal Oncology
45. A novel non‐invasive model for the prediction of advanced liver fibrosis in chronic hepatitis B patients with NAFLD
    Jian Wang, Rui Huang, Jiacheng Liu, Ruimin Lai, Yilin Liu, Chuanwu Zhu, Yuanwang Qiu, Zebao He, Shengxia Yin, Yuxin Chen et al. · 2023 · Journal of Viral Hepatitis
46. Farnesyl diphosphate synthase exacerbates nonalcoholic steatohepatitis via the activation of AHR‐CD36 axis
    Jun Liu, Xinxin Zhang, Yufei Zhang, Minyi Qian, Maohui Yang, Song Tao Yang, Lirui Wang · 2023 · The FASEB Journal
47. Towards collaborative management of non‐alcoholic fatty liver disease: a ‘real‐world’ pathway for fibrosis risk assessment in primary care
    Kelly Lee Hayward, Benjamin J. McKillen, Leigh Ula Horsfall, Carolyn McIvor, Katerina Liew, Jo Sexton, Amy L Johnson, Katharine M. Irvine, Patricia Casarolli Valery, Steven McPhail et al. · 2021 · Internal Medicine Journal
48. Combined impact of alcohol consumption and metabolic syndrome on liver dysfunction in an elderly Chinese population
    Yanrong Zhao, Xiaoxue Yuan, Tianxiang Lin, Qing Yang, Xuewen Jiang, Song Tao Yang, Yinwei Qiu · 2024 · Diabetology & Metabolic Syndrome
49. Diagnostic Value of Ultrasound in Fatty Liver Disease
    Thomas Karlas, Valentin Blank, Albrecht Böhlig · 2021 · Ultraschall in der Medizin - European Journal of Ultrasound
50. A Novel Non-Invasive Approach Based on Serum Ceruloplasmin for Identifying Non-Alcoholic Steatohepatitis Patients in the Non-Diabetic Population
    Qingling Wang, Da Zhou, Mingjie Wang, Mingyu Zhu, Peizhan Chen, Hu Li, Lu Monroe Meng, Xinxin Zhang, Xizhong Shen, Taotao Liu et al. · 2022 · Frontiers in Medicine
51. The additive effect of genetic and metabolic factors in the pathogenesis of nonalcoholic fatty liver disease
    Yuya Seko, Kanji Yamaguchi, Kota Yano, Yusuke Takahashi, Kento Takeuchi, Seita Kataoka, Michihisa Moriguchi, Yoshito Itoh · 2022 · Scientific Reports
52. Dietary Patterns and Long-Term Outcomes in Patients with NAFLD: A Prospective Analysis of 128,695 UK Biobank Participants
    Zhening Liu, Hangkai Huang, Jiarong Xie, Chengfu Xu · 2023 · Nutrients
53. Impact of metabolic risk factors on hepatic and cardiac outcomes in patients with alcohol- and non-alcohol-related fatty liver disease
    Ji Hyae Lim, Hyunji Sang, Ha Il Kim · 2023 · JHEP Reports
54. Comparison of Clinical Characteristics and Outcomes of MAFLD and NAFLD in Chinese Health Examination Populations
    Xin Xu, Xiaohua Zhou, Ting Tian, Yuqing Ding, Chengxiao Yu, Wei Guang Zhao, Xiao Wang, Jing Lu, Wen Guo, Longfeng Jiang et al. · 2023 · Journal of Clinical and Translational Hepatology
55. Sodium-glucose cotransporter-2 inhibitors improve liver enzymes in patients with co-existing non-alcoholic fatty liver disease: a systematic review and metanalysis
    Waseem Amjad, Adnan Malik, Waqas Qureshi, Brittany Burns Dennis, Mirrah Mumtaz, Rabbia Haider, Shakeel Muhammad Jamal, Faisal Jaura, Aijaz Ahmed · 2022 · Gastroenterology Review
56. ONBLR: An effective optimized ensemble ML approach for classifying liver cirrhosis disease
    Dhanalaxmi Badvath, M. Aruna Safali, Sai chaitanya Kumar Gunupudi, Parish venkata Kumar Kuricheti · 2024 · Biomedical Signal Processing and Control
57. Serum Irisin, Myostatin, and Myonectin Correlate with Metabolic Health Markers, Liver Disease Progression, and Blood Pressure in Patients with Metabolic Dysfunction-Associated Fatty Liver Disease and Hypertension
    A. Sheptulina, E. M. Mamutova, Anastasia Yu Elkina, Yuriy S Timofeev, V. A. Metelskaya, A. Kiselev, O. Drapkina · 2024 · Metabolites
58. Liver fibrotic burden across the spectrum of hypothyroidism
    Tingting Du, Yuchai Huang, Yongman Lv, Gang Yuan · 2024 · Journal of Gastroenterology
59. AGA Clinical Practice Update on Risk Stratification and Emerging Surveillance Strategies for Hepatocellular Carcinoma: Expert Review
    Nicole E. Rich, Augusto Villanueva, Jorge A. Marrero, Fasiha Kanwal · 2026 · Gastroenterology
60. Association between arterial hypertension and liver outcomes using polygenic risk scores: a population-based study
    Fredrik O. Åberg, Katri Kantojärvi, Ville Männistö, Anna But, Veikko V Salomaa, Teemu Niiranen, Martti A. Färkkilä, Panu K. Luukkonen, Satu Männistö, Annamari Lundqvist et al. · 2022 · Scientific Reports
61. Surveillance of the progression and assessment of treatment endpoints for nonalcoholic steatohepatitis
    Yiwen Shi, Jian‐Gao Fan · 2022 · Clinical and Molecular Hepatology
62. Hepatocellular carcinoma in patients with metabolic dysfunction-associated fatty liver disease: Can we stratify at-risk populations?
    E Fassio, Fernando Javier Barreyro, M Soledad Pérez, Diana Dávila, Graciela Landeira, Gisela Gualano, Gabriela Ruffillo · 2022 · World Journal of Hepatology
63. From NAFLD to MAFLD: Not just a change in the name
    Jing Zeng, Jian‐Gao Fan · 2022 · Hepatobiliary & pancreatic diseases international
64. NAFLD‐Related Hepatocellular Carcinoma and the Four Horsemen of the Apocalypse
    José Daniel Debes, André Boonstra, Robert Jacobus de Knegt · 2020 · Hepatology
65. Association of Components of Metabolic Syndrome and the Progression of Nonalcoholic Fatty Liver Disease
    Phuc Le, Moosa Tatar, Michael B. Rothberg, Laura Wilson, Daniela S. Allende, Anna Mae Diehl, Rohit Seth Loomba, Naga Chalasani, Brent A. Neuschwander‐Tetri, Kris V. Kowdley et al. · 2025 · The American Journal of Gastroenterology
66. Hepatic Outcomes in Lean Versus Nonlean Metabolic Dysfunction–Associated Steatotic Liver Disease: Propensity‐Matched Cohort Study
    Rishi Chowdhary, Manjeet Kumar Goyal, Ashita Rukmini Vuthaluru, Megh Patel, Tanisha Sehgal, Kirti Arora, Rahul Chowdhary, Varun Mehta, Akash Batta, Omesh Goyal · 2026 · Hepatology Research
67. Incidence and predictors of hepatocellular carcinoma in NAFLD without diagnosed cirrhosis: a nationwide real-world U.S. study
    Daniel Q. Huang, Sally Tran, Scott Douglas Barnett, Biyao Zou, Yee Hui Yeo, Ramsey C Cheung, Mindie H. Nguyen · 2023 · Hepatology International
68. SEOM-GEMCAD-TTD clinical guidelines for the management of hepatocarcinoma patients (2023)
    Carlos López, Mariona Calvo, Juan Carlos Cámara, Beatriz García-Paredes, Carlos Gómez-Martín, Ana María López, Roberto Pazo-Cid, Javier Sastre, Ricardo Yayá, Jaime Feliú · 2024 · Clinical & Translational Oncology
69. USP13 ameliorates nonalcoholic fatty liver disease through inhibiting the activation of TAK1
    Min Ming Tang, Han Cao, Yunqin Ma, Shuangshuang Yao, Xiaohui Wei, Yijiong Tan, Fang liu, Yongde Peng, Nengguang Fan · 2024 · Journal of Translational Medicine
70. Risk factors of hepatocellular carcinoma associated with nonalcoholic fatty liver disease: Systematic review and meta-analysis
    Huimin Yin, Zhanjie Yan, Fangcheng Zhao · 2024 · Technology and Health Care
71. Prognostication in NAFLD: physiological bases, clinical indicators, and newer biomarkers
    Francesca Terracciani, Andrea Falcomatà, Paolo Gallo, Antonio Picardi, Umberto Vespasiani Gentilucci · 2022 · Journal of Physiology and Biochemistry
72. Association between daily aspirin therapy and risk of hepatocellular carcinoma according to metabolic risk factor burden in non‐cirrhotic patients with chronic hepatitis B
    C.-K. Lee, Yun Bin Lee, Hyemi Moon, Jong‐Won Chung, Eun Ju Cho, Jeong‐Hoon Lee, Su Jong Yu, Yoon Jun Kim, Juneyoung Lee, Jung‐Hwan Yoon · 2023 · Alimentary Pharmacology & Therapeutics
73. A retrospective observational study to assess the cirrhosis risk in alcoholic patients
    Paspula Soumya, Thurupu Priya, Hameed Qureshi, Alisha Firdous · 2021 · Cellular Molecular and Biomedical Reports
74. A prospective study on the role of non-invasive tests in the evaluation of diabetes mellitus associated steatotic liver disease
    Zülal İstemihan, Fatih Bektaş, Ali Emre Bardak, Cansu Kızıltaş, Gamze Kemeç, Ziya İmanov, İbrahim Volkan Şenkal, Kanan Nuriyev, Aynura Rustamzade, Sezen Genç Uluçeçen et al. · 2025 · Scientific Reports
75. Incidence of Hepatocellular Carcinoma in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Reconstructed Individual Patient Data Meta-Analysis
    Ryan Yanzhe Lim, Faith Xin Ning Tan, Glenn Jun Kit Ho, Ethan Kai Jun Tham, Alfred Wei Chieh Kow, Guoyue Lv, Zhongqi Fan, Nicholas L. X. Syn, Masahito Nakano, Wenhao Li et al. · 2025 · Clinical Gastroenterology and Hepatology
76. Molecular mechanisms of liver carcinogenesis related to metabolic syndrome
    C. Campani, J. Nault · 2022 · Hepatoma Research
77. Implementing the right care in the right place at the right time for non-alcoholic fatty liver disease (NAFLD-RRR study): a study protocol for a community care pathway for people with type 2 diabetes
    Lucy Gracen, Kelly Lee Hayward, Melanie Aikebuse, Anthony William Russell, James P. O’Beirne, Steven McPhail, Katharine M. Irvine, Suzanne Williams, Patricia Casarolli Valery, Elizabeth Ellen Powell · 2022 · BMC Health Services Research
78. Impact of metabolic factors on risk of cardiovascular disease in nondiabetic metabolic dysfunction-associated fatty liver disease
    Min Kyu Kang, Yu Rim Lee, Se Young Jang, Won Young Tak, Young Oh Kweon, Jeong Eun Song, Rohit Seth Loomba, Soo Young Park, Jung Gil Park · 2023 · Hepatology International
79. Chronic Hepatitis C Related Steatotic Liver Disease Is More Than “Miscellaneous Steatotic Liver Disease”
    Chung‐Feng Huang, Ming‐Lun Yeh, Chia‐Yen Dai, Jee‐Fu Huang, Wan‐Long Chuang, Ming‐Lung Yu · 2024 · Clinical Gastroenterology and Hepatology
80. Age‐dependent effects of diabetes and obesity on liver‐related events in non‐alcoholic fatty liver disease: Subanalysis of CLIONE in Asia
    Yuya Seko, Miwa Kawanaka, Hideki Fujii, Michihiro Iwaki, Hideki Hayashi, Hidenori Toyoda, Satoshi Oeda, Hideyuki Hyogo, Asahiro Morishita, Kensuke Munekage et al. · 2022 · Journal of Gastroenterology and Hepatology
81. Evolution of characteristics of MASLD with and without diabetes: a meta-analysis of placebo arms
    Han Ah Lee, Hye Ah Lee, Hwi Young Kim · 2024 · Scientific Reports
82. Mechanism of liver x receptor alpha in intestine, liver and adipose tissues in metabolic associated fatty liver disease
    Kaiwen Lei, Yan Chen, Jian‐Xing Wu, Yiyu Lin, Yan Bai, Hua Cao, Qishi Che, Jiao Guo, Zhengquan Su · 2025 · International Journal of Biological Macromolecules
83. The change of non-alcoholic fatty liver disease is associated with risk of incident diabetes
    Congling Chen, Yuecheng Zhang, Yujuan Fan, Zhen Ying, Qing Su, Xiaoying Li, Li Qin · 2023 · Frontiers in Endocrinology
84. Lower prevalence of elevated liver stiffness measurements in people with type 2 diabetes taking sodium-glucose co-transporter 2 inhibitors or glucagon-like peptide-1 receptor agonists
    Lucy Gracen, Withma Muthukumara, Melanie Aikebuse, Anthony William Russell, James P. O’Beirne, Katharine M. Irvine, Suzanne Williams, Gaurav Puri, Patricia Casarolli Valery, Kelly Lee Hayward et al. · 2023 · Annals of Hepatology
85. Lean body mass index is a marker of advanced tumor features in patients with hepatocellular carcinoma
    Andrew S. deLemos, Jing Zhao, Milin Patel, Banks Kooken, Karan Mathur, Hieu Nguyen, Areej Mazhar, Maggie S. J. McCarter, Heather N. Burney, Carla D. Kettler et al. · 2024 · World Journal of Hepatology
86. Overweight with HBV infection limited the efficacy of TACE in hepatocellular carcinoma by inhibiting the upregulated HMGB1
    Yuze Sun, Hao Zhang, Ye‐qiang Chen, Chunxue Wu, Miao‐Ling Chen, Huirong Xu, Shuo Wang, Jingzhou Liu, Jianjun Han · 2021 · BMC Cancer
87. NAFLD and HCC: Time to Bridge the Gap
    George T. Cholankeril, Fasiha Kanwal · 2021 · Hepatology
88. Pathogenesis and management of metabolic dysfunction-associated steatohepatitis-related hepatocellular carcinoma: a narrative review
    Han Ah Lee · 2024 · Ewha Medical Journal
89. Metabolic dysfunction-associated steatotic liver disease in Egypt: Epidemiology, risk factors and management challenges
    Walaa Abdelhamed, Mona A. Amin, Imam A. Waked, Mohamed El‐Kassas · 2025 · World Journal of Gastroenterology
90. Screening for At-Risk Nonalcoholic Fatty Liver Disease in the Primary Care Setting
    Esteban Urias, Vincent Lingzhi Chen · 2023 · Seminars in Liver Disease
91. Identifying Patients with Nonalcoholic Fatty Liver Disease in Primary Care: How and for What Benefit?
    Andrew D. Schreiner, Naveed A. Sattar · 2023 · Journal of Clinical Medicine
92. The Growing Landscape of NAFLD-Associated Hepatocellular Carcinoma and Its Impact in Surveillance
    Mariana Verdelho Machado · 2023 · GE Portuguese Journal of Gastroenterology
93. Metabolic health phenotype better predicts subclinical atherosclerosis than body mass index-based obesity phenotype in the non-alcoholic fatty liver disease population
    Yaqin Wang, Ting Yuan, Shuwen Deng, Xiaoling Zhu, Yuling Deng, Xuelian Liu, Lei Liu, Changfa Wang · 2023 · Frontiers in Nutrition
94. Immunotherapy as a Complement to Surgical Management of Hepatocellular Carcinoma
    Susan J. Kim, Kaelyn C. Cummins, Allan Tsung · 2024 · Cancers
95. Machine learning-based identification of biochemical markers to predict hepatic steatosis in patients at high metabolic risk
    Yuan Tian, Hang-Yi Zhou, Ming‐Lin Liu, Yi Ruan, Zhaoxian Yan, Xiao-Hua Hu, Juan Du · 2025 · World Journal of Gastroenterology
96. Circulating messenger RNA variants as a potential biomarker for surveillance of hepatocellular carcinoma
    Timothy M. Block, Daniel Zezulinski, David Edward Kaplan, Jingqiao Lü, Samantha Zanine, Tingting Zhan, Cataldo Doria, Aejaz Sayeed · 2022 · Frontiers in Oncology
97. Hypertension and Histopathology Severity of Non-Alcoholic Fatty Liver Disease Among Adults with Obesity: A Cross-Sectional Study
    Diego Chambergo‐Michilot, Paola K. Rodrigo-Gallardo, Mariella R. Huamán, Angie Z. Vasquez-Chavesta, Gustavo Salinas-Sedo, Carlos Jesus Toro-Huamanchumo · 2023 · Clinical and Experimental Gastroenterology
98. Clinical and cost-effectiveness analysis of community-based screening strategies for non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus
    Roberta Forlano, Tijana Stanic, Sahan Jayawardana, Benjamin Harvey Mullish, Michael S. Yee, Elias A. Mossialos, Robert David Goldin, Salvatore Petta, Emmanuel A. Tsochatzis, Mark R. Thursz et al. · 2022 · Research Square
99. Inverse association between serum lipid profiles and hepatocellular carcinoma risk: a meta-analysis of epidemiological studies
    C. Zeng, Shuran Liu, Haining Li, Xiao Wei Han · 2025 · Frontiers in Oncology
100. Increased Prevalence of Advanced Metabolic Dysfunction-Associated Steatotic Liver Disease Fibrosis in Type 2 Diabetics Despite Low-Risk Fibrosis-4 Index Scores
     Jordan S. Woodard, Gary A. Abrams · 2024 · Journal of Endocrinology and Metabolism